Skip to main content Skip to main content
Go to homepage

Fesoterodine for Children with Bladder Over activity

Safety and Efficacy of Fesoterodine in Children with Bladder Overactivity


Fesoterodine is a drug approved in Europe and USA to treat an overactive bladder condition known in adults but due to lack of research it is not yet FDA approved for children. This bladder condition has been associated with damage to the nervous system and is known as Neurogenic detrusor over activity (NDO).

The purpose of this trial is to study the effects of the Fesoterodine medicine provided to children diagnosed with NDO. We will also compare the effects of Fesoterodine with Oxybutynin, a widely approved medicine commonly used to treat NDO in children.

For more information visit:

Who May Qualify?:

Children between 6-17 years of age diagnosed with neurogenic detrusor overactivity (NDO).

Study Status:
Study Sponsor:

Pfizer, Inc.

Full IRB Study Title:
A 24-week Randomized, Open-label, Study To Evaluate The Safety And Efficacy Of Fesoterodine In Subjects Aged 6 To 17 Years With Symptoms Of Detrusor Over activity Associated With A Neurological Condition (Neurogenic Detrusor Over activity)
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email
Lead Investigator
Daniel McMahon, MD

Director, Pediatric Urology; Pediatric Urologist
Pediatric UrologyKidney Stone Clinic

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.